Dihydromorelloflavone



Compound IDCDAMM01490
Common nameDihydromorelloflavone
IUPAC name8-[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-2,3-dihydrochromen-3-yl]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-2,3-dihydrochromen-4-one
Molecular formulaC30H22O11

Experimental data

Retention time13.27
Adduct[M+H]+
Actual mz559.131
Theoretical mz559.123
Error14.53
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score7.1797

Identifiers and class information

Inchi keyIMIXFUXOSFSXPC-UHFFFAOYNA-N
SmilesO=C1C2=C(O)C=C(O)C(=C2OC(C3=CC=C(O)C(O)=C3)C1)C4C(=O)C=5C(O)=CC(O)=CC5OC4C6=CC=C(O)C=C6
SuperclassPhenylpropanoids and polyketides
ClassFlavonoids

Pharmacokinetic properties

Number of descriptor values(#stars)5
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)7
Number of reactive functional groups (#rtvFG)0
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)558.497
Computed dipole moment(dipole)5.798
Total solvent accessible surface area (SASA)782.012
Hydrophobic component of SASA (FOSA)55.064
Hydrophilic component of SASA (FISA)385.093
Pie component of the SASA (PISA)341.855
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1475.18
Number of hydrogen bond donors (donorHB)5
Number of hydrogen bond acceptors (accptHB)8.75
Free energy of solvation of dipole (dip^2/V)0.0227881
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0250196
Globularity descriptor (glob)0.801399
Predicted polarizability in cubic angstroms (QPpolrz)51.653
Predicted hexadecane/gas partition coefficient (QPlogPC16)18.202
Predicted octanol/gas partition coefficient (QPlogPoct)30.911
Predicted water/gas partition coefficient (QPlogPw)20.944
Predicted octanol/water partition coefficient (QPlogPo/w)2.003
Predicted aqueous solubility (QPlogS)-5.808
Conformation-independent predicted aqueous solubility (CIQPlogS)-8.363
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-6.376
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)2.208
Predicted brain/blood partition coefficient (QPlogBB)-3.856
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)0.666
Predicted skin permeability, log Kp (QPlogKp)-6.74
PM3 calculated ionization potential (IP(ev))8.98
PM3 calculated electron affinity (EA(eV))0.417
Number of likely metabolic reactions (#metab)11
Prediction of binding to human serum albumin (QPlogKhsa)0.424
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)5.958
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)210.747
Number of nitrogen and oxygen atoms (#NandO)11
Number of violations of Lipinski’s rule of five (RuleOfFive)3
Number of violations of Jorgensen’s rule of three (RuleOfThree)3

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P43166CA7Carbonic anhydrase VIIT37541SEA
P22748CA4Carbonic anhydrase IVT53378SEA
P11926ODC1Ornithine decarboxylaseT60366SEA
Q92731ESR2Estrogen receptor betaT80896SEA
P11511CYP19A1Cytochrome P450 19A1T13260SEA
P03372ESR1Estrogen receptor alphaT02506SEA
P06870KLK1Kallikrein 1T40000SwissTargetPrediction and SEA
P20151KLK2Kallikrein 2T01908SwissTargetPrediction and SEA
P15692VEGFAVascular endothelial growth factor AT20761SEA
P49763PGFPlacenta growth factorT70792SEA
Q9UNQ0ABCG2ATP-binding cassette sub-family G member 2T56556SEA
P52209PGD6-phosphogluconate dehydrogenaseT76497SEA
Q16678CYP1B1Cytochrome P450 1B1T92521SEA
P16152CBR1Carbonyl reductase [NADPH] 1T70518SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T53378DI0046Bacterial infection[ICD-11: 1A00-1C4Z]P22748CA4
T53378DI0166Glaucoma[ICD-11: 9C61]P22748CA4
T53378DI0372Seborrhoeic dermatitis[ICD-11: EA81]P22748CA4
T60366DI0020African trypanosomiasis[ICD-11: 1F51]P11926ODC1
T80896DI0062Breast cancer[ICD-11: 2C60-2C6Y]Q92731ESR2
T80896DI0108Cushing syndrome[ICD-11: 5A70]Q92731ESR2
T80896DI0254Menopausal disorder[ICD-11: GA30]Q92731ESR2
T80896DI0432Vasomotor/allergic rhinitis[ICD-11: CA08]Q92731ESR2
T13260DI0062Breast cancer[ICD-11: 2C60-2C6Y]P11511CYP19A1
T13260DI0108Cushing syndrome[ICD-11: 5A70]P11511CYP19A1
T02506DI0106COVID-19[ICD-11: 1D6Y]P03372ESR1
T01908DI0213Innate/adaptive immunodeficiency[ICD-11: 4A00]P20151KLK2
T20761DI0095Colorectal cancer[ICD-11: 2B91]P15692VEGFA
T20761DI0365Retinopathy[ICD-11: 9B71]P15692VEGFA
T20761DI0430Vascular system developmental anomaly[ICD-11: LA90]P15692VEGFA
T70792DI0095Colorectal cancer[ICD-11: 2B91]P49763PGF
T56556DI0218Irritable bowel syndrome[ICD-11: DD91]Q9UNQ0ABCG2
T56556DI0366Rheumatoid arthritis[ICD-11: FA20]Q9UNQ0ABCG2
T76497DI0337Pituitary gland disorder[ICD-11: 5A60-5A61]P52209PGD
T70518DI0037Asthma[ICD-11: CA23]P16152CBR1

Copyright © 2025